Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

CS rates increased with protraction and decreased with retraction. by Paul Hage (21071783)

Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”

The small blue circles show the IC-volume (mean of left and right) from 72 males and the small red squares from 51 females as a function of age. by Pingling Kwok (14896191)

Subjects:

Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

CCND1 is a target gene of miR-1247-3p. by Dequan Wang (6007007)

C-terminal tagging of NCAPH2 can either increase or decrease protein expression. by Gillian C. A. Taylor (3909568)

Enrichment Analysis Based on Ferroptosis-Related Differentially Expressed Genes. by Jiyong Zhang (2498740)

(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. by Long Li (6555)

miR-1247-3p was downregulated in tissues of patients with CRC and was associated with prognosis and drug resistance. by Dequan Wang (6007007)

Evolutionary transitions of gamete dimorphism and gametogenesis induction cues in volvocine algae. by Hiroko Kawai-Toyooka (382362)

Discovery of Novel Isoxazole-Based Small-Molecule Toll-Like Receptor 8 Antagonists by Troy Matziol (20726239)

Subjects:

Discovery of Novel Isoxazole-Based Small-Molecule Toll-Like Receptor 8 Antagonists by Troy Matziol (20726239)

Subjects:

Discovery of Novel Isoxazole-Based Small-Molecule Toll-Like Receptor 8 Antagonists by Troy Matziol (20726239)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”